Friedreich ataxia: An update on animal models, frataxin function and therapies

Advances in Experimental Medicine and Biology

Volumn 652, Issue , 2009, Pages 247-261

  González Cabo, Pilar ^a   Vicente Llorens, José ^b   Palau, Francesc ^b   Dolores Moltó, Maria ^b  

^a INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^b NONE

Author keywords

Antioxidant therapy; Frataxin; Friedreich ataxia; Histone deacetylase inhibitors; Iron chelators Recombinant human erythropoietin; Iron sulfur clusters Oxidative stress; Mitochondria; Oxidative phosphorylation

Indexed keywords

2 PYRIDYLCARBOXYALDEHYDE 2 THIOPHENECARBOXYL HYDRAZONE; ALPHA TOCOPHEROL; ANTIOXIDANT; DEFERIPRONE; FRATAXIN; HEMIN; IDEBENONE; IRON CHELATING AGENT; MITOQUINONE; RECOMBINANT ERYTHROPOIETIN; UBIDECARENONE; UNCLASSIFIED DRUG; IRON BINDING PROTEIN;

CHELATION THERAPY; CONFERENCE PAPER; DRUG MECHANISM; EXPERIMENTAL STUDY; FRATAXIN GENE; FRIEDREICH ATAXIA; GENE; HUMAN; IRON METABOLISM; MITOCHONDRIAL RESPIRATION; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; PATHOLOGY; REVIEW;

ANIMALIA;

ANIMALS; DISEASE MODELS, ANIMAL; FRIEDREICH ATAXIA; HUMANS; IRON-BINDING PROTEINS;

EID: 77950354456     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-90-481-2813-6_17     Document Type: Conference Paper

References (109)

1. Friedreich N. Über degenerative Atrophie der spinalen Hinterstránge. Virchows Arch Pathol Anat 1863;27:1-26.
2. Friedreich N. Über degenerative Atrophie der spinalen Hinterstränge. Virchows Arch Pathol Anat 1863;26(433-459).
3. Lopez-Arlandis JM, Vilchez JJ, Palau F, et al. Friedreich's ataxia: an epidemiological study in Valencia, Spain, based on consanguinity analysis. Neuroepidemiology 1995;14(1):14-19.
4. Polo JM, Calleja J, Combarros O, et al. Hereditary ataxias and paraplegias in Cantabria, Spain. An epidemiological and clinical study. Brain 1991; 114 ( Pt 2):855-866.
5. Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996;335 (16):1169-1175. (Pubitemid 26339770)
6. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271 (5254):1423-1427. (Pubitemid 26089479)
7. Chamberlain S, Shaw J, Rowland A, et al. Mapping of mutation causing Friedreich's ataxia to human chromosome 9. Nature 1988;334(6179):248-250.
8. Cossee M, Schmitt M, Campuzano V, et al. Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A 1997;94(14):7452-7457.
9. Montermini L, Andermann E, Labuda M, et al. The Friedreich ataxia GAA triplet repeat: premutation and normal alleles. Hum Mol Genet 1997;6(8):1261-1266. (Pubitemid 27351065)
10. Bidichandani SI, Ashizawa T, Patel PI. Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion. Am J Hum Genet 1997;60(5):1251-1256. (Pubitemid 27194113)
11. Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997;6(11):1771-1780. (Pubitemid 27460350)
12. Grabczyk E, Mancuso M, Sammarco MC. A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res 2007;35(16):5351-5359. (Pubitemid 47423909)
13. Grabczyk E, Usdin K. The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res 2000;28(14):2815-2822. (Pubitemid 30488540)
14. *TTC repeats induce epigenetic changes and reporter gene silencing in a molecular model of Friedreich ataxia. Nucleic Acids Res 2008;36(19):6056-6065.
15. Al-Mahdawi S, Pook M, Chamberlain S. A novel missense mutation (L198R) in the Friedreich's ataxia gene. Hum Mutat 2000;16(1):95.
16. Bartolo C, Mendell JR, Prior TW. Identification of a missense mutation in a Friedreich's ataxia patient: implications for diagnosis and carrier studies. Am J Med Genet 1998;79(5):396-399. (Pubitemid 28445453)
17. Cossee M, Durr A, Schmitt M, et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999;45(2):200-206. (Pubitemid 29072366)
18. De Castro M, Garcia-Planells J, Monros E, et al. Genotype and phenotype analysis of Friedreich's ataxia compound heterozygous patients. Hum Genet 2000;106(1):86-92. (Pubitemid 30156399)
19. De Michele G, Filla A, Cavalcanti F, et al. Atypical Friedreich ataxia phenotype associated with a novel missense mutation in the X25 gene. Neurology 2000;54(2):496-499. (Pubitemid 30078093)
20. Doudney K PM, Al-Mahdawi S, Carvajal J, Hillerman R, Chamberlain S. A novel site mutation (384+1G-A) in the Friedreich's ataxia gene. Hum Mutat 1997;11:415.
21. Forrest SM, Knight M, Delatycki MB, et al. The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene. Neurogenetics 1998;1(4):253-257. (Pubitemid 128685081)
22. Labuda M P,Ja, PM. A missense mutation (W155R) in an American patients with Friedreich ataxia. Hum Mutat 1999;13:506-507.
23. McCormack ML, Guttmann RP, Schumann M, et al. Frataxin point mutations in two patients with Friedreich's ataxia and unusual clinical features. J Neurol Neurosurg Psychiatry 2000;68(5):661-664. (Pubitemid 30248838)
24. Pook MA, Al-Mahdawi SA, Thomas NH, et al. Identification of three novel frameshift mutations in patients with Friedreich's ataxia. J Med Genet 2000;37(11):E38.
25. Zhu D, Burke C, Leslie A, et al. Friedreich's ataxia with chorea and myoclonus caused by a compound heterozygosity for a novel deletion and the trinucleotide GAA expansion. Mov Disord 2002;17(3):585-589. (Pubitemid 36040975)
26. Zuhlke C, Laccone F, Cossee M, et al. Mutation of the start codon in the FRDA1 gene: linkage analysis of three pedigrees with the ATG to ATT transversion points to a unique common ancestor. Hum Genet 1998;103(1):102-105. (Pubitemid 28398394)
27. Branda SS, Cavadini P, Adamec J, et al. Yeast and human frataxin are processed to mature form in two sequential steps by the mitochondrial processing peptidase. J Biol Chem 1999;274(32):22763-22769.
28. Koutnikova H, Campuzano V, Koenig M. Maturation of wild-type and mutated frataxin by the mitochondrial processing peptidase. Hum Mol Genet 1998;7(9):1485-1489. (Pubitemid 28429930)
29. Schmucker S, Argentini M, Carelle-Calmels N, et al. The in vivo mitochondrial two-step maturation of human frataxin. Hum Mol Genet 2008;17(22):3521-35231.
30. Dhe-Paganon S, Shigeta R, Chi YI, et al. Crystal structure of human frataxin. J Biol Chem 2000;275(40):30753-30756.
31. Gibson TJ, Koonin EV, Musco G, et al. Friedreich's ataxia protein: phylogenetic evidence for mitochondrial dysfunction. Trends Neurosci 1996;19(11):465-468. (Pubitemid 26359860)
32. Babcock M, de Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997;276(5319):1709-1712. (Pubitemid 27421980)
33. Foury F, Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett 1997;411(2- 3):373-377. (Pubitemid 27301488)
34. Koutnikova H, Campuzano V, Foury F, et al. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat Genet 1997;16(4):345-351. (Pubitemid 27323298)
35. Radisky DC, Babcock MC, Kaplan J. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J Biol Chem 1999;274(8): 4497-4499.
36. Wilson RB, Roof DM. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat Genet 1997;16(4):352-357. (Pubitemid 27323299)
37. Cavadini P, Gellera C, Patel PI, et al. Human frataxin maintains mitochondrial iron homeostasis in Saccharomyces cerevisiae. Hum Mol Genet 2000;9(17):2523-2530.
38. Canizares J, Blanca JM, Navarro JA, et al. dfh is a Drosophila homolog of the Friedreich's ataxia disease gene. Gene 2000;256(1-2):35-42.
39. Llorens JV, Navarro JA, Martinez-Sebastian MJ, et al. Causative role of oxidative stress in a Drosophila model of Friedreich ataxia. Faseb J 2007;21(2):333-344. (Pubitemid 46213481)
40. Anderson PR, Kirby K, Hilliker AJ, et al. RNAi-mediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum Mol Genet 2005;14(22):3397-3405. (Pubitemid 41672124)
41. Cossee M, Puccio H, Gansmuller A, et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 2000;9(8):1219-1226. (Pubitemid 30248608)
42. Das N, Levine RL, Orr WC, et al. Selectivity of protein oxidative damage during aging in Drosophila melanogaster. Biochem J 2001;360(Pt 1):209-216. (Pubitemid 33081966)
43. Prabhu HR, Krishnamurthy S. Ascorbate-dependent formation of hydroxyl radicals in the presence of iron chelates. Indian J Biochem Biophys 1993;30(5):289-292.
44. Anderson PR, Kirby K, Orr WC, et al. Hydrogen peroxide scavenging rescues frataxin deficiency in a Drosophila model of Friedreich's ataxia. Proc Natl Acad Sci U S A 2008;105(2):611-616. (Pubitemid 351171756)
45. Runko AP, Griswold AJ, Min KT. Overexpression of frataxin in the mitochondria increases resistance to oxidative stress and extends lifespan in Drosophila. FEBS Lett 2008;582(5):715-719.
46. Adamec J, Rusnak F, Owen WG, et al. Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia. Am J Hum Genet 2000;67(3):549-562. (Pubitemid 30659586)
47. Ventura N, Rea S, Henderson ST, et al. Reduced expression of frataxin extends the lifespan of Caenorhabditis elegans. Aging Cell 2005;4(2):109-112. (Pubitemid 41632910)
48. Vazquez-Manrique RP, Gonzalez-Cabo P, Ros S, et al. Reduction of Caenorhabditis elegans frataxin increases sensitivity to oxidative stress, reduces lifespan, and causes lethality in a mitochondrial complex II mutant. Faseb J 2006;20(1):172-174. (Pubitemid 43100504)
49. Zarse K, Schulz TJ, Birringer M, et al. Impaired respiration is positively correlated with decreased life span in Caenorhabditis elegans models of Friedreich Ataxia. Faseb J 2007;21(4):1271-1275. (Pubitemid 46495716)
50. Puccio H, Simon D, Cossee M, et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 2001;27(2):181-186. (Pubitemid 32157445)
51. Simon D, Seznec H, Gansmuller A, et al. Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. J Neurosci 2004;24(8):1987-1995. (Pubitemid 38292812)
52. Miranda CJ, Santos MM, Ohshima K, et al. Frataxin knockin mouse. FEBS Lett 2002;512(1- 3):291-297. (Pubitemid 34164497)
53. Al-Mahdawi S, Pinto RM, Ruddle P, et al. GAA repeat instability in Friedreich ataxia YAC transgenic mice. Genomics 2004;84(2):301-310. (Pubitemid 38834168)
54. Al-Mahdawi S, Pinto RM, Varshney D, et al. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 2006;88(5):580-590. (Pubitemid 44540244)
55. Clark RM, De Biase I, Malykhina AP, et al. The GAA triplet-repeat is unstable in the context of the human FXN locus and displays age-dependent expansions in cerebellum and DRG in a transgenic mouse model. Hum Genet 2007;120(5):633-640. (Pubitemid 44942847)
56. Waldvogel D, van Gelderen P, Hallett M. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann Neurol 1999;46(1):123-125. (Pubitemid 29314392)
57. Lamarche JB, Cote M, Lemieux B. The cardiomyopathy of Friedreich's ataxia morphological observations in 3 cases. Can J Neurol Sci 1980;7(4):389-396. (Pubitemid 11205157)
58. Rotig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 1997;17(2):215-217.
59. Foury F. Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain. FEBS Lett 1999;456(2):281-284. (Pubitemid 29352308)
60. Park S, Gakh O, Mooney SM, et al. The ferroxidase activity of yeast frataxin. J Biol Chem 2002;277(41):38589-38595. (Pubitemid 35154719)
61. Park S, Gakh O, O'Neill HA, et al. Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. J Biol Chem 2003;278(33):31340-31351. (Pubitemid 36994654)
62. Cook JD, Bencze KZ, Jankovic AD, et al. Monomeric yeast frataxin is an iron-binding protein. Biochemistry 2006;45(25):7767-7777. (Pubitemid 44185493)
63. Nichol H, Gakh O, O'Neill HA, et al. Structure of frataxin iron cores: an X-ray absorption spectroscopic study. Biochemistry 2003;42(20):5971-5976. (Pubitemid 36605099)
64. Cavadini P, O'Neill HA, Benada O, et al. Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia. Hum Mol Genet 2002;11(3): 217-227. (Pubitemid 34173351)
65. Levi S, Corsi B, Bosisio M, et al. A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem 2001;276(27):24437-24440.
66. Campanella A, Isaya G, O'Neill HA, et al. The expression of human mitochondrial ferritin rescues respiratory function infrataxin-deficient yeast. Hum Mol Genet 2004;13(19): 2279-2288. (Pubitemid 39359926)
67. Becker EM, Greer JM, Ponka P, et al. Erythroid differentiation and protoporphyrin IX downregulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization. Blood 2002;99(10): 3813-3822. (Pubitemid 34534556)
68. Yoon T, Cowan JA. Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J Biol Chem 2004;279(25):25943-25946. (Pubitemid 38798734)
69. Lesuisse E, Santos R, Matzanke BF, et al. Iron use for haeme synthesis is under control of the yeast frataxin homologue (Yfh1). Hum Mol Genet 2003;12(8):879-889. (Pubitemid 36504030)
70. Lange H, Muhlenhoff U, Denzel M, et al. The heme synthesis defect of mutants impaired in mitochondrial iron-sulfur protein biogenesis is caused by reversible inhibition of ferrochelatase. J Biol Chem 2004;279(28):29101-29108. (Pubitemid 38915781)
71. Napoli E, Taroni F, Cortopassi GA. Frataxin, iron-sulfur clusters, heme, ROS, and aging. Antioxid Redox Signal 2006;8(3-4):506-516.
72. Napoli E, Morin D, Bernhardt R, et al. Hemin rescues adrenodoxin, heme a and cytochrome oxidase activity in frataxin-deficient oligodendroglioma cells. Biochim Biophys Acta 2007;1772(7):773-780. (Pubitemid 46900883)
73. Muhlenhoff U, Richhardt N, Ristow M, et al. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum Mol Genet 2002;11(17): 2025-2036. (Pubitemid 34919277)
74. Duby G, Foury F, Ramazzotti A, et al. A non-essential function for yeast frataxin in ironsulfur cluster assembly. Hum Mol Genet 2002;11(21):2635-2643. (Pubitemid 35174693)
75. Lill R, Diekert K, Kaut A, et al. The essential role of mitochondria in the biogenesis of cellular iron-sulfur proteins. Biol Chem 1999;380(10):1157- 1166. (Pubitemid 29516404)
76. Lill R, Muhlenhoff U. Iron-sulfur protein biogenesis in eukaryotes: components and mechanisms. Annu Rev Cell Dev Biol 2006;22:457-486.
77. Yoon T, Cowan JA. Iron-sulfur cluster biosynthesis. Characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. J Am Chem Soc 2003;125(20):6078-6084. (Pubitemid 36582978)
78. Gerber J, Muhlenhoff U, Lill R. An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. EMBO Rep 2003;4(9):906-911. (Pubitemid 37304409)
79. Ramazzotti A, Vanmansart V, Foury F. Mitochondrial functional interactions between frataxin and Isu1p, the iron-sulfur cluster scaffold protein, in Saccharomyces cerevisiae. FEBS Lett 2004;557(1-3):215-220. (Pubitemid 38115898)
80. Shan Y, Napoli E, Cortopassi G. Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones. Hum Mol Genet 2007;16(8):929-941. (Pubitemid 47062737)
81. Kondapalli KC, Kok NM, Dancis A, et al. Drosophila frataxin: an iron chaperone during cellular Fe-S cluster bioassembly. Biochemistry 2008;47(26):6917-6927. (Pubitemid 351898946)
82. Bulteau AL, O'Neill HA, Kennedy MC, et al. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 2004;305(5681):242-245. (Pubitemid 38886737)
83. Lodi R, Cooper JM, Bradley JL, et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci U S A 1999;96(20):11492-11495. (Pubitemid 29487408)
84. Ristow M, Pfister MF, Yee AJ, et al. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc Natl Acad Sci U S A 2000;97(22):12239-12243.
85. Busi MV, Zabaleta EJ, Araya A, et al. Functional and molecular characterization of the frataxin homolog from Arabidopsis thaliana. FEBS Lett 2004;576(1-2):141-144. (Pubitemid 39330472)
86. Gonzalez-Cabo P, Vazquez-Manrique RP, Garcia-Gimeno MA, et al. Frataxin interacts functionally with mitochondrial electron transport chain proteins. Hum Mol Genet 2005;14(15):2091-2098. (Pubitemid 41418009)
87. Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 2001;49(5):590-596. (Pubitemid 32429786)
88. Hart PE, Lodi R, Rajagopalan B, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005;62(4):621-626. (Pubitemid 40489896)
89. Geromel V, Darin N, Chretien D, et al. Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol Genet Metab 2002;77(1- 2):21-30. (Pubitemid 35178511)
90. Mariotti C, Solari A, Torta D, et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003;60(10):1676-1679. (Pubitemid 36618100)
91. Ribai P, Pousset F, Tanguy ML, et al. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch Neurol 2007;64(4):558-564. (Pubitemid 46588346)
92. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, et al. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 1999;354(9177):477-479. (Pubitemid 29368927)
93. Di Prospero NA, Baker A, Jeffries N, et al. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007;6(10):878-886. (Pubitemid 47404985)
94. Pineda M, Arpa J, Montero R, et al. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol 2008;12(6):470-475.
95. Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001;276(7):4588-4596.
96. Jauslin ML, Meier T, Smith RA, et al. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. Faseb J 2003;17(13):1972-1974.
97. Boddaert N, Le Quan Sang KH, Rotig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007;110(1):401-408. (Pubitemid 47026862)
98. Kakhlon O, Manning H, Breuer W, et al. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood 2008;112(13):5219-5227.
99. Goncalves S, Paupe V, Dassa EP, et al. Deferiprone targets aconitase: implication for Friedreich's ataxia treatment. BMC Neurol 2008;8:20.
100. Lim CK, Kalinowski DS, Richardson DR. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2- pyridylcarboxaldehyde isonicotinoyl hydrazone class. Mol Pharmacol 2008;74(1):225-235. (Pubitemid 351872173)
101. Siren AL, Ehrenreich H. Erythropoietin-a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001;251(4):179-184.
102. Smith KJ, Bleyer AJ, Little WC, et al. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003;59(3):538-548. (Pubitemid 38368670)
103. Sturm B, Stupphann D, Kaun C, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest 2005;35(11):711-717. (Pubitemid 41640907)
104. Grant L, Sun J, Xu H, et al. Rational selection of small molecules that increase transcription through the GAA repeats found in Friedreich's ataxia. FEBS Lett 2006;580(22):5399-53405.
105. Dervan PB, Edelson BS. Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr Opin Struct Biol 2003;13(3):284-299. (Pubitemid 36782454)
106. Burnett R, Melander C, Puckett JW, et al. DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA.TTC repeats in Friedreich's ataxia. Proc Natl Acad Sci U S A 2006;103(31):11497- 11502. (Pubitemid 44182480)
107. Sarsero JP, Li L, ,Wardan H, et al. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J Gene Med 2003;5(1):72-81. (Pubitemid 40310369)
108. Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006;2(10):551-8. (Pubitemid 44413238)
109. Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 2008;3(4):e1958.